Previous 10 | Next 10 |
Mrs. King, the company’s founding CEO, will remain a Director and advisor to support transition GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its Board of Directors has appointed Harout Semerjian as chief executive officer (CEO), effective August 6, 2021, to...
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Thursday, August 5, 2021, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and ...
GlycoMimetics (GLYC) announces that the first patient was treated in an early-stage study evaluating the company’s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine ((LDAC)) in patients with treated secondary acute myeloid leukemia ((ts-AML)).The ...
Trial to study uproleselan combination in patients with high-risk treated secondary AML GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b/2 study evaluating the company’s lead drug candidate, uproleselan, a...
GlycoMimetics Inc. (NASDAQ:GLYC) traded at a new 52-week low today of $1.96. So far today approximately 203,000 shares have been exchanged, as compared to an average 30-day volume of 663,000 shares. GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discove...
Shares of GlycoMimetics Inc. (NASDAQ:GLYC) traded at a new 52-week low today of $2.02. This new low was reached on below average trading volume as 203,000 shares traded hands, while the average 30-day volume is approximately 684,000 shares. Potential upside of 1.8% exists for GlycoMimeti...
Shares of GlycoMimetics Inc. (NASDAQ:GLYC) traded at a new 52-week low today of $2.02. This new low was reached on below average trading volume as 203,000 shares traded hands, while the average 30-day volume is approximately 684,000 shares. GlycoMimetics Inc. (NASDAQ:GLYC) has potential ...
GlycoMimetics (GLYC) announces that dosing has started in the study of a combination of the company's uproleselan in treating certain patients with acute myeloid leukemia ((AML)).The investigator-sponsored trial by University of California ((UC)) Davis Comprehensive Cancer Center is eval...
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at University of California (UC) Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with venetoclax and azacitidine for the treatment of older or unfit pat...
ToughBuilt Industries (TBLT) -29% ToughBuilt Industries launches $40M direct offeringAerpio Pharmaceuticals (ARPO) -8%.Nova LifeStyle (NVFY) -9%.UTStarcom Holdings (UTSI) -7%.GlycoMimetics (GLYC) -6%.Digital Brands Group (DBGI) -5%. For further details see: Aerpio Pharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
2024-06-26 06:35:00 ET A Short Guide to Different Order Types With Penny Stocks Understanding the various order types can significantly enhance your strategy when trading penny stocks. Penny stocks represent an exciting opportunity for investors seeking to enter the stock market at ...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 6.8% to $126.09 on volume of 414,790,976 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 18.7% to $0.265 on volume of 162,165,405 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 12.6%...